MON, FEB 24, 2020 08:30 CET

RLS Global continues to develop its Wound Care business area and sells off the dental care portfolio

RLS Global’s strategy is to ensure a strong market penetration for ChloraSolv together with regional/global partnerships. ChloraSolv is based on a unique buffered hypochlorite technology with documented clinical results within Advanced Wound Care. During 2020, RLS will initiate pre-clinical activities with the aim of broadening the product portfolio within new clinical areas. New clinical indications that RLS will evaluate are burns and other clinical indications outside Wound Care.

With the given background, RLS Global will sell off its Dental Care portfolio in order to optimize the company’s resources. RLS will sell PeriSolv to REGEDENT AG. The transaction consists of a cash payment of 4 MSEK and an additional consideration until 2032 based on a percentage of products sold. REGEDENT will take the investments required to ensure that PeriSolv is MDR compliant and market access to new markets. PeriSolv’s future owner is focused on the dental area and has a broad portfolio in periodontology and Maxillofacial Surgery.

“With the ongoing commercialization of ChloraSolv and the positive feedback we have received so far, it is a strategic decision to discontinue with the Dental Care portfolio and focus resources on further development of our technical platform”, says Karin Fischer CEO RLS Global.

During the year, RLS intention is to find a buyer for CariSolv as well.

For more information, please contact:
Karin Fischer, CEO RLS Global AB,
+46 (0)702 48 46 51,

Anders Husmark, CBDO RLS Global AB,
+46 (0)72 450 94 03,

This information is information that RLS Global AB (public) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10thof April, 2019, at 08:00.

Press Release